AU7234900A - Iron-partial hydrolyzates of casein complexes and processes for preparation thereof - Google Patents
Iron-partial hydrolyzates of casein complexes and processes for preparation thereof Download PDFInfo
- Publication number
- AU7234900A AU7234900A AU72349/00A AU7234900A AU7234900A AU 7234900 A AU7234900 A AU 7234900A AU 72349/00 A AU72349/00 A AU 72349/00A AU 7234900 A AU7234900 A AU 7234900A AU 7234900 A AU7234900 A AU 7234900A
- Authority
- AU
- Australia
- Prior art keywords
- casein
- iron
- solution
- hydrolyzates
- partial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical class NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title claims description 246
- 238000000034 method Methods 0.000 title claims description 49
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000005018 casein Substances 0.000 claims description 232
- 235000021240 caseins Nutrition 0.000 claims description 216
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 197
- 239000000243 solution Substances 0.000 claims description 174
- 229910052742 iron Inorganic materials 0.000 claims description 113
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 84
- 230000007062 hydrolysis Effects 0.000 claims description 44
- 238000006460 hydrolysis reaction Methods 0.000 claims description 44
- -1 iron ion Chemical class 0.000 claims description 38
- 239000004365 Protease Substances 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 36
- 108091005804 Peptidases Proteins 0.000 claims description 34
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 30
- 239000007864 aqueous solution Substances 0.000 claims description 28
- 239000002244 precipitate Substances 0.000 claims description 20
- 235000019606 astringent taste Nutrition 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 229910001868 water Inorganic materials 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 2
- FSLJQBWNDCKEHA-UHFFFAOYSA-N S.SS Chemical compound S.SS FSLJQBWNDCKEHA-UHFFFAOYSA-N 0.000 claims 1
- 235000019419 proteases Nutrition 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 25
- 238000009826 distribution Methods 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000011259 mixed solution Substances 0.000 description 13
- 239000007853 buffer solution Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 235000013365 dairy product Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 208000007502 anemia Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 150000002506 iron compounds Chemical class 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000008366 buffered solution Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- QPRMGHKASRLPJP-UHFFFAOYSA-N 12-(5-hydroxy-6-methylpiperidin-2-yl)dodecan-2-one Chemical compound CC1NC(CCCCCCCCCCC(C)=O)CCC1O QPRMGHKASRLPJP-UHFFFAOYSA-N 0.000 description 4
- 101100366328 Caenorhabditis elegans spe-27 gene Proteins 0.000 description 4
- OGPQOSAKRHKIHW-UHFFFAOYSA-N Cassin Natural products CC(CCCCCCCCCC1CCC(O)C(C)N1)C(=O)C OGPQOSAKRHKIHW-UHFFFAOYSA-N 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000011790 ferrous sulphate Substances 0.000 description 4
- 235000003891 ferrous sulphate Nutrition 0.000 description 4
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229960001322 trypsin Drugs 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000025371 Taste disease Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 2
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000019656 metallic taste Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100316805 Caenorhabditis elegans spe-5 gene Proteins 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 241000208465 Proteaceae Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- APVZWAOKZPNDNR-UHFFFAOYSA-L iron(ii) citrate Chemical compound [Fe+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O APVZWAOKZPNDNR-UHFFFAOYSA-L 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical class [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Our Ref:7563920 P/00/011 Regulation 3:2
AUSTRALIA
Patents Act 1990
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT Applicant(s): Snow Brand Milk Products Co., Ltd.
36-108 Naebo-cho 6-chome Higashi-ku Sappro City Japan DAVIES COLLISON CAVE Patent Trade Mark Attorneys Level 10, 10 Barrack Street SYDNEY NSW 2000 Address for Service: Invention Title: Iron-partial hydrolyzates of casein complexes and processes for preparation thereof The following statement is a full description of this invention, including the best method of performing it known to me:- 5020 P:\WPDO\CRJSPECI\7091471..p..do.rII 1100
SPECIFICATION
Iron-partial hydrolyzates of casein complexes and processes for preparation thereof Field of the Invention This invention relates to iron-partial hydrolyzates of casein complexes. Furthermore, this invention relates to processes for the preparation of iron-partial hydrolyzates of casein complexes.
The iron-partial hydrolyzates of casein complexes of the present invention have characteristic features of thermoresistance or thermostability without exhibiting iron characteristic astringent taste after heat sterilization and can exist in aqueous solution. Thus, the compounds of the present invention are useful as raw materials of foods and drinks, medicines and feeds for prevention and treatment of anemia, and reinforcement of iron content in the body. Furthermore, the iron-partial hydrolyzates of casein complexes of the present invention have advantages that they exhibit favorable taste and can be handled easily in the production procedure without loss of the solid content because they do not aggregate in aqueous solution.
20 Background of the Invention .o The iron uptake of Japanese has been maintained at about 100% sufficiency without change since 1975, and iron can be said as a nutrient in meals that must be taken with care. In the world, iron is considered as a nutrient which is often liable to be deficient, particularly supply of iron enriched foods and medicines for persons with anemic tendency, and pregnant and nursing females is desired. However, addition of an iron salt such as iron sulfate or citrate as an iron reinforcing agent in foods and drinks has drawbacks to cause a problem of characteristic astringent taste when added in foods and drinks and anxiety of injury of gastrointestinal mucosa, thus the amount of addition is limited. Furthermore, an organic iron compound, heme iron, causes problems in taste such as metallic or fishy taste and its addition to foods is highly limited.
Addition of milk casein, amino acid or casein phosphopeptide has been tried for the improved absorption of iron [Japanese Laid-open Patent Application No. 162843 (1984)].
P:\WPDOCS\CRN\SPEC\709141 .spedoc-2 1/I I0 However, these methods could not diminish characteristic astingent taste of iron without reducing the amount of its addition.
The inventors of the present invention developed to reduce the characteristic astringent taste of iron by binding iron with casein [Japanese Laid-open Patent Application No. 83400 (1990)]. However, the iron casein prepared by binding iron with casein is devoid of thermostability and shows characteristic astringent taste of iron by thermal pasteurization at for 10 minutes, 120'C for 2-3 seconds or retort pasteurization. This was considered to be caused by release of iron from casein due to weak binding of iron and casein, and formation of iron hydroxides or the like.
Then, the inventors of the present invention further investigated and found that the binding of iron and casein can be reinforced by using carbonic acids and/or hydrogencarbonic acid and succeeded to get iron-casein complexes [Japanese Laid-open Patent Application No. 259572 (1995)]. The iron-casein complexes are thermoresistant without showing iron characteristic astringent taste even by heat sterilization and are useful as raw materials of foods and drinks, medicines, feeds and so forth for prevention and treatment of anemia and reinforcement of iron content. However, iron-casein complexes had drawbacks of tendency to aggregate by dissolution in water, difficult to treat in the production procedure and liable to lose sold mass.
Furthermore, their sandy taste remains to be solved.
o* *o* *oo o t P:\WPDOCS\CRNSPECRI70914 .spc.do-21/ IM0
I-
Disclosure of the Invention The present invention relates to iron-partial hydrolyzates of casein complexes containing 1- 1,000 atoms of iron per one molecule of casein prior to hydrolysis with a protease. The solubility of the dried powder of complexes in water is at least 15% without aggregation or precipitation even after heating at 90'C for 10 minutes, and the solution is free of iron characteristic astringent taste.
The complexes contain preferably one or more molecule of carbonic acid and/or hydrogencarbonic acid per one molecule of casein prior to the hydrolysis.
The above mentioned complexes of the present invention is thermoresistant without showing iron characteristic astringent taste by heat sterilization, aggregation in aqueous solution or precipitation by heating at 90'C for 10 minutes.
The iron-partial hydrolyzates of casein complexes can be prepared by the following two procedures.
That is, the first produce is formation of iron-casein complexes, followed by partial hydrolysis of casein with a protease.
The iron-casein 25 3 25 oo ooo complexes used in the procedure can be prepared by 1) simultaneous mixing a solution containing carbonic acid, hydrogencarbonic acid, or a carbonic acid and a hydrogencarbonic acid (solution a solution containing iron (solution B) and a solution containing casein (solution 2) mixing carbonic acid, hydrogencarbonic acid. or oarbonic acid and/or hydrogencarbonic acid (solution and a solution containing iron and casein (solution B), or 3) mixing a solution containing carbonic acid, hydrogencarbonic acid, or carbonic acid and a hydrogencarbonic acid, and casein (solution A) and an iron containing solution (solution B).
In the process the molar concentration of iron ion in solution B is made 1/3 or less to those of carbonic acid and hydrogencarbonic acid ions dissolved in a mixed solution of A, B and C. The molar concentration of casein in solution C is adjusted to 1-1/1,000 to that of iron ion in solution B. In the process the molar concentration of iron ion in solution B is made 1/3 or less to those of carbonic acid and hydrogencarbonic acid ions in a mixture of solutions A and B. and the molar number of casein in solution B is adjusted to 1-1/1,000 to that of iron ion in solution
B.
In addition, in the process the molar concentration of iron ion in solution B is made 1/3 or less to those of carbonic acid and hydrogencarbonic acid ions in a mixed solutions A and B, and the molar number of casein in solution A is adjusted to 1-1/1,000 to that of iron ion in solution B.
eo ""The second procedure is a process of partial hydrolysis of casein with a protease in advance to give partial hydrolyzates of casein, and to give iron-partial hydrolyzates of casein complexes from the partial hydrolyzates of casein. In other words, iron-partial hydrolyzates of casein complexes are obtained by ixing i) carbonic acid, hydrogencarbonic acid, or carbonic and hydrogencarbonic acid, ii) iron, and iii) casein partial S. hydrolyzates prepared by partial hydrolysis of casein with a protease to react to form •eeoc
J
iron-partial hydrolyzates of casein complexes.
In the above mentioned second procedure, mixing of the aforementioned three components can be carried out by the following methods, that is: 1) Simultaneous mixing a solution containing carbonic acid.
hydrogencarbonic acid, or carbonic acid and hydroqencarbonic acid (solution a solution containing iron (solution and a solution of partial hydrolyzates of casein solution (solution
C).
2) Mixing a solution containing carbonic acid, hydrogencarbonic acid, or a carbonic acid and hydroqencarbonic acid (solution A) and a solution containing iron and a partial hydrolyzate of casein prepared by partial hydrolysis of casein with a protease (solution
B).
3) Mixing a solution containing a partial hydrolyzate of casein prepared, by partial hydrolysis of casein with a protease and carbonic acid, hydrogencarbonic acid, or carbonic acid and a hydrogencarbonic acid (solution A) and a solution containing iron (solution B).
In the procedure 1) the molar concentration of iron ion in solution B is made 1/3 or less to those of carbonic acid and hydrogencarbonic acid ions dissolved in a mixed solution of A, B and C, and molar number of partial hydrolyzates of casein in solution
C
is adjusted to 1-1/1,000 molar number of iron ion in solution
B
calculated as casein before partial hydrolysis.
In the procedure the molar concentration of iron ion in solution B is made 1/3 or less to those of a carbonic acid and a hydrogencarbonic acid ions dissolved in a mixed solution of A and B, and the molar number of hydrolyzates of casein in solution B is adjusted to 1-1/1,000 to that of iron ion in solution B calculated as casein before hydrolysis.
Further, in the procedure the molar concentration of iron ion in solution B is made 1/3 or less to those of carbonic acid and hydrogencarbonic acid ions dissolved in a mixed solution of A and B, S and the molar number of casein partial hydrolyzed product in solution A is adjusted to 1-1/1,000 to that of iron ion in solution B calculated as casein before partial hydrolysis. o oo~ Thus. the iron-partial hydrolyzates of casein complexes can be prepared to give following properties of 1) to 4).
1) The complexes contain 1-1,000 atoms of iron and preferably one or more molecule of a carbonic acid and/or a hydrogencarbonic acid per one molecule of casein prior to the hydrolysis, 2) the dried powder of complexes dissolves in water to give at least 15% solution, 3) the aqueous solution gives no precipitate by heating at 90C for minutes, and 4)the solution gives no iron characteristic astringent taste.
The iron-partial hydrolyzates of casein complexes of the present invention do not form precipitates in the aqueous solution after heating at 90 0 C for 10 minutes, and this thermoresistance is derived from the use of partial and enzymic hydrolyzates of casein as a raw material. The enzymic hydrolysis is preferably carried out with a protease to give partial hydrolyzates, no more than 55% of which is a hydrolyzate with molecular weight of 15,000 or more.
T
The present invention is practically explained at first by S. processes for preparation of the complexes.
The first processes composed of preparation of iron-casein complex, followed by partial hydrolysis of the iron-casein complex with a protease to give iron-partial hydrolyzates of casein complex are explained.
The processes have following three variations of to Simultaneous mixing solution containing carbonic acid, hydrogencarbonic acid, or carbonic acid and hydrogencarbonic acid (solution solution containing iron (solution and a solution contain~ing caaein (solution C) to give a iron-casein complex. However, the molar concentration of iron ion in solution B is made 1/3 or less to those of a carbonic acid and a hydrogencarbonic acid ions dissolved in a mixed solution of A, B and C. The molar number of casein in solution C is adjusted to 1-1/1,000 to that of iron ion in solution a. The iron-casein complex is partially hydrolyzed with a protease to give the iron-partial hydrolyzates of casein complex of the present invention.
Mixing of a solution containing carbonic acid.
hydrogencarbonic acid, or carbonic acid and hydrogencarbonic acid (solution and a solution containing iron and casein (solution B) to give the complex of iron-cassin complex. However, the molar concentration of iron ion in solution a Is made 1/3 or less ofthose of a carbonic acid and a hydrogencarbonic acid ions dissolved in a mixed solution of A and B, and the molar number of casein in solution B is adjusted to 1-1/1,000 to that of iron ion In solutilon B. The iron-casein complex is par-tially hydrolyzed with a protease to give the carbonic iron-partial hydrolyzates of casein complex of the present invention.
Mixing a solution containing a carbonic acid, hydrogencarbonic acid, or carbonic acid and hydrogencarbonic acid, and casein (solution and a solution containing iron (solution B) to give the complex of iron-casein complex. However, the molar concentration of iron ion in *solution B is made 1/3 or less Of those Of carbonic acid and hydrogencarbortic acid ions dissolved in a mixed solution of A and 3, and the molar nuber of casein in solution A is adjusted to 1 1/1,000 to that Of iron ion in solution B. The -iron-case in complex is partially hydrolyzed with a protease to give the iron-partial hydrolyzates of cassin complex of the present invention- In the second method, that is the procedures for the production of iron-partial hydrolyzates of casein complex from partial hydrolyzates of casein prepared by partial hydrolysis of casein with a protease in advance include the following to variations: W1) Simultaneous mfixinig a solution containing carbonic acid.
hydrogerncarbonic acid-, or carbonic acid and hydrogencarbonic acid (solution A) a solution containing iron (solution B) and a solution of partial kivdrolyzates or casein solution (soluti.on C) using hydrolyzates of casein prepared by partial hydrolysis of casein with~ a protease ina advance to give iron-partial hydxolyzates of casein complex of the present invention. However, the molar concentration of iron ion in solution B is made 1/3 or less of those of carbonic acid and hydroqencarbonic acid ions dissolved in a mixed solution of A. B and C, and molar number of partial hydrolyzates of casein in solution C is adjusted to 1-1/1,000 molar number of iron ion in solution B calculated as casein before partial hydrolysis- M~ixing a solution containing carbonic acid, hydrogencarbonic acid, or carbonic acid and hydrogencarbonic acid (solution A) and a solution containing iron. and a partial hydrolyzate of casein (solution B) using hydrolyzates of casein pzepared by partial hydrolysis of casein with a protease in advance to give a iron-partial hydrolyzar-es of casein complex. Hiowever, the molar concentration of iron ion in solution B is made 1/3 or leas of those of carbonic acid and hy'drogencarbonic acid ions dissolved in a mixed solution of A and B. The molar number of partial hydrolyzates of casein In soluionB is adjusted to 1-1/1,000 molar number o rnini souioB calculated as casein. before hydzolysis. o rnini Mixing a solution containing carbonic acid, hydrogencarbonic acid, or carbonic acid and hydrogencarbonic acid, and partial hydrolyzates of casein prepared by partial hydrolysis of ****casein with a protease in advance (solution A) and a solution containing iron (solution B) to give a iron-partial hydrolyzates of casein complex. However, the molar concentration of iron ion in solution B is made 1/3 or less of those of carbonic acid and hydrogencarbonic acid ions dissolved in a mixed solution of A and B. The molar number of partial hydrolyzates of casein in solution A is adjusted to 1-1/1,000 molar number of iron ion in solution B calculated as casein before hydrolysis.
Further, in the third method, the water soluble iron-partial hydrolyzates of casein complex can be obtained as an aqueous solution containing most of iron by removal of precipitates in the aqueous solution of iron-partial hydrolyzates of casein complex when above mentioned first or second procedure forms these precipitates in the aqueous solution. The partial hydrolyzates of casein is preferably those having molecular weight of 15,000 or more at ratios of not more than in the total composition.
The aqueous solution is preferably cooled for the formation of precipitates at 15 0 C or lower, more preferably at 10 0 C or lower for three hours or longer and still more preferably stand still for five hours or longer. The removal of precipitates is carried out by decantation or centrifugation. Thus, 70-94% of the water soluble iron-partial hydrolyzates of casein complex can be industrially and advantageously remained in the supernatant.
The carbonic acid and/or hydrogencarbonic acid in the present invention maybe used as free acids or water soluble salts for preparation of the iron casein complexes or iron-partial hydrolyzates of casein complexes. The iron compounds in the present invention are generally used in water soluble salt forms.
The carbonic acid and/or hydrogencarbonic acid, iron compounds, and casein or partial hydrolyzates of casein may be used as solutions or in solid form such as salts for the preparation re of iron casein complexes or iron-partial hydrolyzates or casein complexes in the present inventions. Solid state carbonic acid and/or hydrogencarbonic acid, iron compounds, and casein or partial hydrolyzates of casein may be simultaneously dissolved and used.
The casein used in the present invention may be illustrated, for example, as casein, acidic casein, casein sodium, lactic casein, acasein, -casein and a -casein isolated from milk of manmals such as human being and cattle. These casein are commercially available or as methods to massively isolate them are known, products produced by these methods may also be used. 'In addition, those produced by microorganisms, animal cells and transgenic animals using gene "technology may also be used. When crude casein such as mixtures of 1':\WPDOCSkCRN\SPECI\7914.SPE -27/5/99 as -caaein, 0 -casein and ic -casein is used as a raw material, the molar concentration of cazein in the solution is estimated from average molecular weight based on the ratios of the components.
The carbonic acid and/or hydrogencarbonic acid used in the present invention may be illustrated as carbonated water, ammonium hydrogencarbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium carbonate, calcium carbonate and so forth- Iron compounds such as water soluble iron salts, for example trivalent iron compounds including ferric chloride and ferric sulfate and bivalent iron compounds including ferrous nitrate, ferrous sulfate and ferrous citrate may be illustrated. The pH adjusting agent such as sodium hydroxide, ammonia, potassium hydroxide, hydrochloric acid, citric acid and lactic acid may be simultaneously used. The reaction mixture is generally adjusted at pH 2-9.
In the present invention, a proteolytic enzyme or protease used for partial hydrolysis of ironcasein complexes or casein such as pepsin, trypsin, chymotrypsin, chymosin, pancreatin derived from animals and papain derived from plants may be illustrated. In addition, proteolytic enzymes or proteases prepared by gene recombinant technology may also be used.
The solubility of iron-partial hydrolyzates of casein complex of the present invention largely depends on the distribution of molecular weight of casein hydrolyzates which forms the complex. Thus, the reaction condition for the partial hydrolysis with the proteolytic enzyme should be carefully selected. For example, the distribution of molecular weight of casein hydrolyzates which form the iron-partial hydrolyzates of casein complex of the present invention may be preferably selected at ratios of not over than 55% in total composition with those having molecular weight of 15,000 or more. Futhermore, hydrolyzates of casein having molecular weight of 15,000 or less and 800 or more at ratios of 20% or over, preferably or over in total are preferably used. Furthermore, casein hydrolyzates having molecular weight of 15,000 or over at ratios of less than 55% and those of less than 800 at ratios of over 34% o. in total may be used for the preparation of the water soluble iron-partial hydrolyzates of casein complex of the present invention according to the third invention of the present invention.
Therefore, the partial hydrolysis of casein in the present invention means hydrolysis of casein so as to give casein hydrolyzates having molecular weight of 15,000 or more at 55% or less in total.
Brief _exnlanation of the drawinan.
F* Fig. 1 shows a molecular weight distribution of partial hydrolyzates of lactic casein obtained by Example 3.
Fig. 2 shows a molecular weight distribution of partial hydrolyzates of lactic casein obtained by Example 4.
Fig. 3 shows a molecular weight distribution of partial hydrolyzates of lactic casein obtained by Example Fig. 4 shows a molecular weight distribution of partial hydrolyzates of lactic casoin obtained by Example 6.
Pig. 5 -shows a molecular weight distribution of partial1 hydrolyzates of lactic casein obtained by Example 7.
Fig. 6 shows a molecular weight distribution of of lactic casein obtained by Reference example 1.
Fig. 7 shows a molecular weight distribut-ion of of lactic casein obtained by Reference example 2.
The present invention will be practically explained by the following examples. These examples are shown merely as illustration and not to be constructed to limit the scope of the presen t invention.
(Example 1) (Solution A) One liter of an aqueous solution of 1,200 nnol. soiumw hydrogencarbonate.
(Solution B) 0.2 L of an aqueous solution of ferric chloride containing lOwuol of iron, (Solution C) 0.8 L of an aqueous solution of 0.1 rwnol lactic casein (Dairy Board, New Zealand).
*However, adjustment of molar concentration was cridotwt average molecular weight. The average molecular weight was estimated from respective theoretical molecular weight and composition ratio of a -casein, fi-casein and x -casein determined by urea-sodium- dodecylsulfate (SDS)-electrophoresis.
Solution B 2 L) and solution C L) were mixed to give solution (1 then the mixed solution (U L) was added to solution A (1 L to gv rncsi complex. The solution containing the complex was desalted by treatment with anultrafiltration membrane of 5,000 molecular weight cut, concentrated 'to make casein concentration up to 5% in the coMplex, and adjusted to pH 8.0 by adding sodium hyrgnaroae **In the reaction solution, 1,200 U of protease, trypsin Novo Nordisk)/g casein was added, sodium hydroxide was added to maintain the solution at pH 8.0 and partial hydrolysis of casein was carried out at 50C. The partial hydrolysis was performed till the reaction solution became clear with gross observation. The temperature of the reaction mixture was kept at 851C for 20 minutes to inactivate the enzyme and to tenRinate the reaction. The partial hydrolysis of casein required about 7 hrs. The reaction solution was dialyzed and lyophilized to give 3.0 g of iron-partial hydrolyzates of casein complex.
The solubility of the iron-partial hydrolyzates of casein complex was examined by dissolving the complex in a simulated liquid food buffer containing 0.05 moll imidazole and 0.15 mole sodium chloride (hereinafter referred as a simulated buffer) up to give 15% solution. Thus, the iron-partial hydrolyzates of casein complex completely dissolved without becouming turbid or forming aggregation.
The shelf life of the above mentioned ironpartial hydrolyzates of casein complex was examined in a simulated buffer prepared by dissolving the complex. The simulated buffer solution containing the complex was diluted to give iron concentration of 3.6 mol, heat sterilized at 90C for 10 minutes and kept at 5C. No precipitation was found even after six month storage.
[Example 2] (Solution A) One liter of an aqueous solution of 1,200 mmol sodium hydrogencarbonate.
"*(Solution B) 0.2 L of an aqueous solution of 9 mnol ferric sulfate containing 9mnol of iron.
(Solution C) 0.8 L of an aqueous solution of 0.1 mmnol lactic casein (Sigma Chemical Co.).
Their molar concentrations were adjusted in a similar manner with that of Example 1.
Solution B (0.2 L) and solution C (0.8 L) were mixed to give solution (1 and then the mixed solution (1 L) was added to solution A (1 L) to give a casein complex. The solution containing the complex was desalted by treatment with an 'ultrafiltration memnbrane of 5,000 molecular weight cut, concentrated to make casein concentration up to 5% in the complex, arnd adjusted to pH 8.0 by adding sodium hydroqencarbonat.
In the reaction solution, 600 U of protease, papain (W-40: Amano Pharmaceutical Co., Ltd.) Ig casein was added, sodium hydroxide warn added to mantain the solution at pH 8.0 and partial hydrolysis of casein was carried out at 651C. The partial hydrolysis was performed till the reaction solution became clear with gross observation. The reaction mixture was kept at 85r., for 20 minutes to inactivate the enzyme and to terminate the reaction. The partial hydrolysis required about 6 hra. The reaction solution was dialyzed and lyophilized to give 2.4 g of iron-partlal hydrolyzatex of casein complex.
The solubility of the iron-partial hydrolyzates of caseiLn complex was examined by a similar manner with that of Example 1. Thus, the iron-partial hydrolyzates of cassin complex completely dissolved without becoming turbid or forming aggregation.
The shelf life of the above mentioned ironpartial hydrolyzates of casein complex was examined in a similar manner with that of Example 1. Wo precipitation was found even after six months storage.
[Test,~ example 1] .A sensory evaluation test was carried out for simulated buffer solutions prepared. by dissolution of ironpartial hydrolyzates of casein complexes of Examples 1 and 2. That is, 10 male and 10 female panelists were given the simulated buffer solutions containing iron-partial hydrolyzates of casein complex of Example 1 or 2 and asked whether they f elt astringent taste or not. A blind-fold was given to each panelist to avoid the influence of appearance to the judgment. Test for one samuple wras carried out in an order of the control first and then the sample, and at least one day interval was placed prior to the test of the next sample. Furthermore, the test samples were given randomly to each panelist to avoid the deviation. between test days for evaluation of sample. Similar sensory evaluation test was perf ormed using solution of ferrous sulfate* having iron concentration of 3. 6 mcia, which was e-pected to exhibit astringent taste. The number of panelists who sensed astringent taste is shown in Table 1.
Table 1 Sample Number of panelist who sensed astringent taste Example 1 0/20 Example 2 0/20 Ferrous sulfate 20/20 As shown in Table 1. the Partial hydkolyzates of casein complex of Example I. or 2 has no characteristic astringent taste peculiar to iron.
[Example 3] (Solution A) One liter of anx aqueous solution of 1.200 rmol sodium hydrogenaronat 6 (Solution B) 0 .2 L of an aqueous solution of ferric chloride contaizning 10 zunol of iron- (Solution C) 0. 8 L of an aqueous solution of 0. 1 mnmol of partial hydrolyzates lactic casein calculated as casein before the partial hydrolysis.
The molar concentration was adjusted in a similar manner with that of Example 1.
The partial hydrolyzates of lactic casein used for the preparation of solution C was prepared as shown below. That is, lactic casein (Dairy Board, New Zealand) was dissolved to give 5% reaction solution and sodium hydrogencarbonate was added to adjust the S solution at pH 8.0. A protease, trypsin (PTN6.D.- Novo Nordisk) was added at a ratio of 1,000 U/'g of casemn and partially hydrolyzed S C at SOIt for five hours while maintaining the solution at pH 8.0 by adding -sodium hydroxide. The reaction solution was kept at IRSt for minutes to inactivate the enzymic activity and to terminate the partial hydrolysis. The reaction solution was lyophilized to give 3.1 g of partial hydrolyzates of lactic casein.
The molecular weight of the partial hydrolyzates of lactic case2.n was determined with a gel filtration chromatography. That is, a solution of the partial hydrolyzates of lactic casein was made to flow through a high performance liquid chromatography (HPLC) packed with TSI~ge1 3000PWxl (300 X 7.8 am: Tosoh Corp.) and ainted with a acetonitrile containing 0.1% trifluoroacetic acid at a rate of 0.3 mI/minute. The absorbance of elute at 210 nm was determined.
Similar procedure was carried out using standard protein and peptide with known molecular weights and the elurion time was determined, respectively. The molecular weight and elution time of the standard protein and peptide are shown in Table 2.
Table 2 Molecular weight Elution tim as-Casein 23,000 39.8 (minutes) 0 -Casein 24,000 40.0 Aprotinin 61500 48.8 Insulin B chain 3,496 51.8 Insulin A chain 2,532 55.2 AngiotensuirtH 1,046 58.7 Glutathione 307 64.2 o Molecular weight distribution of partial hydrolyzates of lactic casein was estimated from integrated value of absorbance and elution time in referring to the molecular weigjht and elution time of the 6* standard protein and peptide. The results are shown in Fig. 1. The 0@5 Fig. shows that partial hydrolyzates of lactic casein having molecular weight of 800-15,000 consists 94% of the total product.
see* *000Above mentioned solution B (0.2 L) anid solution C (0.8 L) were mixed to give solution (1 L) and the resultant solution (B+C) (1 L) was added to solution A (1 L) to give Se iron-partial hydrolyzates of casein complex. A so2lution containing the complex was dialyzed and lyophili~zed to give 2.7 g of 0 Ge iron-partial hycdrolyzates of casein complex.
4 0 The dif fusat. of a solution containing ironpartial hydrolyzates of casein complex was concentrated with an evaporator, however no iron content was detected by determination with an emission spectrophotometer (ICr') Therefore, all iron is Considered to be used as a component of ironpartial hydrolyzates of casein complex The shelf life of a simulated buffer solution containing the above iron-partial hydrolyzates of casein complex was determined in a similar manner with that of Example 1 and it was found that the buffered solution shows no precipitation even after storage for six months.
[ExcaMle 41 In a 5% aqueous solution of lactic casein (Dairy Board. New Zealand) sodium hydrogencarbonate was added to adjust the p1% at 0.0. In the reaction solution, a protease, papain (W-40: Amano Pharmaceutical Co., Ltd.) wan added at a rat-io of 10 U/g of canein and the partial hydrolysis was carried out at t for three hours while maintaining pH3 at 8.0 by adding sodim hydroxide. Thereafter, the reaction solution was kept -at 851C for minutes to inactivate the enzyme activity and terminate the reaction.
The treated reaction solution was lyophilized to give 3.4 g of hydzrolyzates of lactic casei.n.
The molecular weicght distribution of the hydrolyzates of lactic casein was determined in a similar manner with that of Examle 3 and the result is shown in Fig. 2. The Fig. shows that hydrolyzates of lactic casein having molecular weight of 800-15,000 consists 45% of *the total product and the rests have molecular weight of* over 15,000.
A iron-partial hydrolyzates of casein complex was prepared in a similar manner with that of Exanple 3 using the above mentioned hydrolyzates of lactic casein coMplex.
The concentration of iron in dif fusate of a solution containing the iron-partial hydrolyzates Of easein complex was determined in a similar Manner with that of Example 3 and no iron was detected. Therefore, all iron is considered to be used as a cmponent of -iron-partial hydrolyzatea of cassin coMpleX.
The solubility of above mentioned iron-partial hydrolyzates of casein complex was examined according to a similar method shown in Example 1. The iron-partial hydrolyzates of casein complex dissolved completely without forming insoluble aggregated mass or any turbid.
The shelf life of a simulated buffer solution containing the above hydroaencarbonic acid-iron-partial hydrolyzates of casein complex was determined in a similar manner with that of Example 1 and it was found that the buffered solution shows no precipitation even after storage for six months.
(Example 53 in a So solution of lactic casein (Dairy Board, New Zealand), sodium hydroqencarbonate was added to Make pH 8.0. in the reaction solution, a protease, -bromelain r .(Amamo Pharmaceutical Co., Ltd.) was added at a ratio of 1,000o U/q of casein and caused to partial hydrolysis at 659C for five hours while maintaining pEH at 8.0 by adding sodium hydroxide. Thereafter, the reaction aolution Vas kept at 85 'C for 20 minutes to inactivate the enzyme activity and terminate the reaction. The treated reaction solution was lyophilized to give 3.0 g of hydrolyzates of lactic casein.
The molecular weight distribution of the hydrolyzates of lactic casein was determined in a similar manner with that of Example 3 and the result is shown in Fig. 3. The Fig. shows that hydrolyzates of lactic casein having molecular weight of 800-15,000 consists 804r of the total product.
A -iron-partial hydrolyzates of casein complex was prepared in a similar manner with that of Example 3 using the above hydrolyzates of l~actic casein complex. The 0 concentration of iron in dif funate of a solution containing the iron-partial hydrolyzates of casein complex was detezininei 'in a similar manner with that of Example 3 and no iron was detected. Therefore, all-iron is considered to be used as a component of iron-partial hydrolyzates of casein complex.
PA\WPDOCS\CRN\SPECI\709141SPE 27/599 The solubility of above mentioned iron-partial hydrolyzates of casein complex was examined according to a similar method shown in Example 1. The iron-partial hydrolyzates of casein complex dissolved completely without forming insoluble aggregated mass or any turbid.
The shelf life of a simulated buffer solution containing the above 20 20 2 o* iron-partial hydrolyzates of casein complex was determined in a similar manner with that of Example 1 and it was found that the buffered solution shows no precipitation even after storage for six months.
[Example 6] In a 5% solution of lactic casein (Dairy Boad, New Zealand) sodium hydrogencarbonate was added to added to adjust the pH at In the reaction solution, a protease, protease P (Amano Pharmaceutical co-, Ltd.) was added at a ratio of 10 U/9 of casein and the partial hydrolys is was carried out, at 45 'C f or five hours while maintaining pH at 8.0 by addition of sodium hydroxide.
Thereafter, the reaction solution was kept at 850C for 20 minutes to inactivate the enzyme activity and terminate the reaction. The treated reaction solution was lyophilized to give 3.1 g of hydrolyzates of lactic casein.
The molecular weight distribution of the hydrolyzates of lactic casein was determined In a similar manner with that of Exanple 3 and the result is shown in Fig. 4. The Fig. shows that hydrolyzates of lactic casein having molecular weight of 800-15,000 consist& 90% of the total product and those having molecular weight of over 15,000 consists 24 of the total product, and further those less than 800 consists 101 of the total product.
A iron-partial hydrolyzates of casein complex was prepared in a similar mannier with that of Example 3 us ing the above mentioned hydrolyzates of lactic cassin compex.
The concentration of iron in diffusate of a solution containing -iron-partial hydrolyzates of casein complex was determined in a similar manner with that of Example 3 and no iron was detected. Therefore, all iron is considered to be used as a component of iron-partial hydrolyzates of casein complex.
The solubility of above mentioned iron-partial hydrolyzates of casein complex was examined according to a similar method shown in Example 1. The iron-partial hydrolyzates of casdin complex dissolved completely without forming insoluble aggregated mass or any turbid.
1I:\WPDOCS\CRN\SPECV7O914 I.SPE 27/5/99 The shelf life of a simulated buffer solution containing the above: mentioned hydrogencarbonic acid-iron-partial hydrolyzates of casein complex was determined in a similar manner with that of Example 1 and it was found that the buffered solution shows no precipitation S.18a even after storage for six months.
(Examaple 7) In a 51k solution of lactic casein (Dairy Board, Now Zealand) -sodium hydrociencaz onate was added to adjust the pH at 7-0- In the reaction solution, a proteas, Fisbase (Kaken Pharma Co., Ltd.) was added at a rate of 1,000 T3/g of casein and the partial hydrolysis was carried out at 50*C for one hour while maintaining pH at 7.0 by adding sodium hydroxide. Thereafter, the reaction solution was kept at 85 tC for 20 minutes to inactivate the enzyme activity and terminate the reaction. The treated reaction solution was lyophilized to give 2.8 g of hydrolyzates of lactic casein.
The molecular weight distribution of the hydrolyzates of lactiLc casein was determined in a similar manner with that of Example 3 and -the result is; shown% In Fig. S. The Fig. shown that hydrolyzates of lactic casein having molecular weight of 800-15,000 consists 66% of the total product arnd the rests have molecular weight of less than 800.
A iron-partial hydrolyzates of casein complex was prepared in a similar marnner with that of Example 3 using the above mentioned hydrolyzates of lactic casein. The concentration of iron in diffusate of a solution containing iron-partial hydrolyzates of casein complex was determined in a similar manner with that of. Example 3 anid no iron was detected. Therefore, all iron is considered to be used as a component of iron-partial hydrolyzates of casein complex.
The solubility of above mentioned iron-partial hydrolyzates of casein complex was examined according to a similar method shown in Example 1. The iron-partial hydrolyzates; of casein complex dissolved completely without forming insoluble aggregated mass or any turbid.
The shelf life of a simulated buf fer solution containing the above mntioned iron-partial hydrolyzates of casein complex was determined in a similar manner with that of Example I and it was found that the buffered solution shows almost no precipitation even after storage for sair. months.
V:\WPDOCSXCRN\SPECI\70914I.SPE 27/5/99 (Test example 23 A sensory evaluation teart was carried out for simulated buffer zolutions of the iron-partial hydrolyzates of I0 casein complexes of Examples 3-7. The sensory evaluation test was carried out in a similar manner with that of Test example 1. The number of panelists who sensed astringent- tazte is shown in Table 3.
Table 3 Sample Number of panelis6ts who sensed astringent taste Example 3 0/20 Example 4 0/20 Example 5 0/20 Example 6 0/20 Example 7 0/20 Ferrous sulfate 20/20 As shown In Table 3, the iron-partiLal hydrolyzates of casain complexess of *Example 3-7 has -no characteristic astringent taste of iron.
[Test example 3) In a saline phosphate buffer (pH 7.2) containing 6.2 mg/l00 g of ascorbic acid and sodium ascorbate as vitamin C, a iron-part-ial hydrolyzates of casein complex of Example 1 (present invention group a iron-partial hydrolyzates of casein complex of Example 3 (present invention group or ferrous sulfa"e (control group 1) was dissolved, respectively, to give iron concentration of 20 mg/l00 ml. The resultant solutions were heat sterilized at 90*C f or 10 minutes to give test samples. A saline phosphate buffer (pH 7.2) containing 6.2 mig/lO0 g of ascorbic acid and sodium ascorbate as vitamin C was heat sterilized at for 10 minutes to give a test sample (control group 2).
Female Wistar rats of 21 days old just after weaning (Charles River Japan, Inc.) with body weight of 45-50 g were selected and fed for two weeks with an. iron deficient feed (iron content of 0.25 mg/100 g of feed, oriental Yeast Co., Ltd.) to prepare anemia rate with blood hemoglobin concentration of 7 9/100 ml blood or less.
The rats were divided in groups each having 8-11 animals'and fed for further six veeks with the iron deficient feed together with 1 mi/day of each of the test samqple given by gavage. After six weeks of administration of test samples, blood was drawn from tail vein of rats and hemoglobin content was determined with an automatic blood cell counter (Toa Medical Electronics Co., Ltd.). The results are shown in Table 4.
Table 4 Hemolobin value (average±tSD) Present invention group 1 16.1±1.3 (g/100 ml) Present invention group 2 15.8±*1.2 Test group 1 11.9±0o.9 Test group 4.S5*0. As *shown in Table Iron-partial: hydrolyzates of casein complexes of Examples 1 and 3 exhibited superior therapeutic effect to anemia than those of ferrous sulfa"e used as tablets.
[Comparative examgple 1) In a5% aqueous solution of lactic casein (Dairy Board, New Zealand), sodium hydrogencarbonate was added to adjust the pH at B.0- In the reaction solution, a protease, papain (W-40: Amano Pharmaceutical Co., Ltd.) was added at a ratio of 10'U/g of casein and the partial hydrolysis was carried out at 65 t for 30 minutes while maintaining PH at 8.0 by addition of -sodium hydroxide.
Thereafter, the reaction solution was kept at 851C for 20 minutes to inactivate the enzyme activity and terminate the partial hydrolysis.
The treated reaction solution was lyophilized to give 3.6 g of hydrolyzates of lactic casein.
The molecular weight distribution of the hydrolyzates of lactic casein was determined in a similar mnanner with that of Example 3 and the result is shown in Fig. The Fig. shows that hydrolyzates of lactic casein having molecular weight of 80'0-15,000 consists 304 of the total product and the rests have molecular weight of over 15,000.
at iron-hydroILYzates of casein complex was prepared in a similar manner with that of E~xample 3 using the above mentioned hydrolyzates of lactic casein. The concentration of iron in diffusate of a solution containing ironhydrolyzates of casein ccu1ex was determined in a similar manner with that of Example 3 and no iron was detect-ed. Therefore, all iron is conaideed to be used as a component of iron-hYdrolyzates of casein cogilex.
A simulated buffer solution prepared by dissolution of the above mentioned iron-partial. hydrolyzates of casein COirPleX was diluted to give iron concentration of 3.6 nunol, and was heat sterilized at 90C for 10 minutes, and kept at SC observing the formation of precipitates. Fozmation of precipitates was found after four hours.
[Comparative example 23 In a 51k aqueous solution of lactic casein (Dairy Board, Now Zealand), sodium hydxogencarbonate was added to adjust the pH at In the reaction 3oluton, a protease, Fishase (Kaken Pharma Co., Ltd.) was added at a rate of 1,000 U/ 9 of casein and caused to partial hydrolysis at 501C for five hours while maintaining pEH at by adding sodium hydroxide. Thereafter, the reaction solution was kept at 851t for 20 minutes to inactivate the enzyme activity and terminate the partial hydrolysis. The treated reaction solution was lyophilized to give 2.5 g of hydrolyzates of lactic casein.
The molecular weight distribution of the hydrolyzates of lactic casein was determined in a similar manner with that of Example 3 and the result is shown in Fig. 7. The Fig. shows that hydrolyzates of lactic casein having molecular weight of 800-15,000 consists 394 of the total product and the rests have molecular weight of less than 800.
A iron-hydrolyzates of casein complex was prepared In a similar manner with that of Examrple 3 using the above hydrolyzate3 of lactic casein. Above mentioned iron-hydrolyzates of casein complex was diluted with the .*simulated buffer solution to give iron concentration of 3.6 mmol and was heat sterilized at 90 r for 10 minutes, then kept at 5 "C observing the formation of precipitates. Formation of precipitates was found after two hours.
As shown by Examples 3-7 and Comparative examples 1-2, it is important to prepare iron-hydrolyzates of casein complex having 55 or less hydrolyzates of casein of molecular weight of over 15,000 and not more than 34% of that of molecular weight of less than 800 to give favorable solubility. If the ratio of partial hydrolyzates of casein with larger or smaller molecular weight goes beyond the above value, the solubility of the iron-hydrolyzates of casein complex decreases.
Comparative Example 3 Determination of iron content in the supernatant and precipitates obtained in Comparative example 2 with ICP revealed the presence of most of iron in the supernatant as shown in Table Thus, industrial removal of the precipitates may provide industrial application of the present invention.
Table Supernatant Precipitates Iron content 95.2 5.0 Therefore, a method for industrial removal of precipitates was variously investigated and a practical method shown below was found. That is, a reaction mixture after preparation of ironpartial hyrdolyzates of casein complex is allowed to stand at 15 0 C or lower, preferably at or lower for three hours, preferably five hours or longer to mature the precipitates. The matured precipitates in the reaction mixture are removed by decantation or centrifugation to give a supernatant containing the water soluble iron-partial hyrdolyzates of casein complex with yield of 70-94% as iron.
S.i P:\WPOOCS\CRN\SPECI\709141 SPE -27/5199 Example 8 A similar method to that of Comparative example 3 gave 2.5 g of hydrolyzates of lactic casein and an increased amount of the enzyme from 1,000 to 2,000 U in the partial hydrolysis in this process also gave 2.5 g of hydrolyzates of lactic casein. In addition, the content of hydrolyzate having molecular weight of less than 800 in their hydrolyzates of lactic casein was 39% and 54%, respectively, in total.
These hydrolyzates of lactic casein as used for the preparation of iron-partial hydrolyzates of casein complex in a similar manner with that of Example 3. The resultant solution containing the iron-partial hydrolyzates of casein complex is allowed to stand at 10 0 C for five hours to mature the precipitates. Thereafter, the reaction mixture is decanted to isolate and solely recover the supernatant.
The solubility of above mentioned iron-partial hydrolyzates of casein complex was examined according to the similar method shown in Example 1. The iron-partial hydrolyzates of casein complex dissolved completely without forming insoluble aggregated mass or any turbid.
In addition, the solution containing the iron-partial hydrolyzates of casein complex is diluted to a concentration of 3.6 mM/L of iron and pasteurized by heating at 90 0 C for minutes. After pasteurization, the solution was kept at 5 0 C, however, no precipitate was observed even after storage for six months.
.Example 9 In 1.2 L of water, 840 mg of sodium hydrogencarbonate was added and mixed well.
Then, 480 mg of hydrolyzates of lactic casein obtained by Example 3 was added and mixed.
Further, 278 mg of ferrous sulfate heptahydrate was added to the solution and thoroughly mixed. The resultant aqueous solution was pasteurized by heating at 90 0 c for 10 minutes to give clear solution without turbid or iron characteristic metallic taste.
The solubility of above mentioned iron-partial hydrolyzates of casein complex was examined according to the similar method shown in Example 1. The iron-partial Shydrolyzates of casein complex dissolved completely without forming insoluble aggregated mass or any turbid.
23a o P:\WPDOCS\CRN'SPECI70914 I.sp.doc-21/ ll 0 Example In 10 L of an aqueous solution prepared according to the method of Example 9, 500g of erythritol, 500 g of fructose and glucose syrup, and 40 g of lactic acid were added.
Furthermore, six grams of a grapefruit flavour was added. The resultant solution was divided into 100 ml each, filled in glass bottles pasteurized by heating at 80'C for minutes. The obtained solution contained iron at a rate of 5 mM/100 ml. The solution was clear without precipitation, turbid or metallic taste of iron even after storage at 37'C for a month.
Applicability for industrial use The iron-partial hydrolyzates of casein complexes of the present invention have thermoresistance or thermostability, without showing iron characteristic astringent taste after heat sterilization and can exist in aqueous solution, and are useful as raw materials for foods and drinks, medicines and feeds for prevention and treatment of anemia and reinforcement of iron content. Furthermore, as their aqueous solutions do not aggregate or precipitate, and can be handled easily in the production procedure, the loss of the solid mass is very little.
The reference to any prior art in this specification is not, and should not be taken as, an 20 acknowledgement or any form of suggestion that the prior art forms part of the common general knowledge in Australia.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
The reference to any prior art in this specification is not, and should not be taken as an acknowledgment or any form of suggestion that, that prior art forms part of the common Sgeneral knowledge in Australia. 23b
Claims (7)
1. Iron-partial hydrolyzates of casein complexes having following properties of 1) to 4): 1) the complexes containing 1-1,000 atoms of iron per one molecule of casein prior to hydrolysis with a protease, 2) the dried powder of the complexes dissolve in water to give at least 15% solution, 3) the aqueous solution shows no precipitation by heating at 90'C for 10 minutes, and 4) the solution shows no iron characteristic astringent taste.
2. The iron-partial hydrolyzates of casein complexes according to Claim 1 wherein carbonic acid- and/or hydrogencarbonic acid-iron-partial hydrolyzates of casein complexes have following properties of 1) to 4): 1) the complexes containing 1-1,000 atoms of iron and one molecule or more of carbonic- acid and/or hydrogencarbonic-acid per one molecule of casein prior to the hydrolysis, 2) the dried powder of the complexes dissolve in water to give at least 15% solution, 3) the aqueous solution shows no precipitation by heating at 90'C for 10 minutes, and 4) the solution shows no iron characteristic astringent taste.
3. The iron-partial hydrolyzates of casein complexes according to Claim 1 or Claim 2 20 wherein the partial hydrolyzates of casein in an enzymically hydrolyzed product with a protease have molecular weights of 15,000 or more at ratios of 55% or less in total product.
4. The process for the production of the iron-partial hydrolyzates of casein complexes 9* according to Claim 1 or Claim 2 wherein iron-casein complexes prepared by a reaction of three compounds of carbonic acid and/or hydrogencarbonic acid, iron and casein are partially hydrolyzed with a protease, with the proviso that the molar concentration of iron ion in preparation of carbonic acid and/or hydrogencarbonic acid-iron-casein complexes is 1/3 or less to those of carbonic and hydrogencarbonic acid ions, and molar number of casein is 1-1/1,000 to that of iron ion. 9 P:\WPDOCS\CRN\SPECIn7OM91 .spc.doc-2 1l00 The process for production of the iron-partial hydrolyzates of casein complexes according to Claim 1 or Claim 2 wherein the process is carried out by mixing i) carbonic acid, hydrogencarbonic acid, or carbonic and hydrogencarbonic acids, ii) iron and iii) partial hydrolyzates of casein prepared by partial hydrolysis of casein with a protease to form their complexes, with the proviso that the molar concentration of iron in the reaction of the three components is 1/3 or less to those of carbonic acid and hydrogencarbonic acid, and molar number of partial hydrolyzates of casein is 1-1/1,000 to that of iron ion calculated as molecule number of casein prior the partial hydrolysis.
6. The process according to Claim 4 or Claim 5 wherein the partial hydrolysis is carried out by enzymic hydrolysis of casein with a protease to give hydrolyzed products having molecular weight of 15,000 or more at ratios of not more than 55% in total.
7. The process for preparation of the iron-partial hydrolyzates of casein complexes characterizing in the process is carried out by removal of precipitates formed in aqueous solution of the iron-partial hydrolyzates of casein complexes prepared according to anyone of Claims 4-6 followed by collection of residual iron-partial hydrolyzates of casein complexes.
8. Iron-partial hydrolyzates of casein complexes or processes for their production, substantially as hereinbefore described with reference to the Examples and/or the accompanying drawings. OS *S DATED this 21st day of November, 2000 :*sea SNOW BRAND MILK PRODUCTS, INC by its Patent Attorneys DAVIES COLLISON CAVE ae S S **S.SS 0 .0.as
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU72349/00A AU7234900A (en) | 1997-03-21 | 2000-12-18 | Iron-partial hydrolyzates of casein complexes and processes for preparation thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9-87378 | 1997-03-21 | ||
AU72349/00A AU7234900A (en) | 1997-03-21 | 2000-12-18 | Iron-partial hydrolyzates of casein complexes and processes for preparation thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU64209/98A Division AU729978B2 (en) | 1997-03-21 | 1998-03-20 | Iron-partial hydrolyzates of casein complexes and processes for preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU7234900A true AU7234900A (en) | 2001-03-08 |
Family
ID=3755055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU72349/00A Abandoned AU7234900A (en) | 1997-03-21 | 2000-12-18 | Iron-partial hydrolyzates of casein complexes and processes for preparation thereof |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU7234900A (en) |
-
2000
- 2000-12-18 AU AU72349/00A patent/AU7234900A/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4172072A (en) | Buffered enzymatically produced metal proteinates | |
ES2746173T3 (en) | Use of proline-specific endoproteases to hydrolyze peptides and proteins | |
US5606086A (en) | Iron lactoferrin complexes and preparation thereof | |
JP2002000225A (en) | Iron-containing protein composition | |
AU729978B2 (en) | Iron-partial hydrolyzates of casein complexes and processes for preparation thereof | |
JPS5854786B2 (en) | Method for producing protein hydrolyzate from whey protein | |
EP0979614B1 (en) | Method of producing iron-whey-proteolysate complex | |
KIM et al. | Recovery of fish bone from hoki (Johnius belengeri) frame using a proteolytic enzyme isolated from mackerel intestine | |
AU7234900A (en) | Iron-partial hydrolyzates of casein complexes and processes for preparation thereof | |
JP2001002583A (en) | Blood sugar level increase inhibitor | |
JP2818827B2 (en) | Iron supplement drink | |
EP0416108A1 (en) | Nutritious composition | |
JP3580517B2 (en) | Iron casein phosphopeptide complex and method for producing the same | |
JP3458606B2 (en) | Mineral solubilizing material | |
JPH0379979B2 (en) | ||
AU739336B2 (en) | Iron-casein complexes and methods for preparation thereof | |
JPH0977793A (en) | Iron-casein complex and its production | |
JPH0369269B2 (en) | ||
JPH0515339A (en) | Protein-like composition, nourishing medicine for serious stress and nourishing medicine for hepatic disease | |
JP2555356B2 (en) | Iron preparation without lipid oxidation and vitamin A deterioration | |
KR100421465B1 (en) | Manufacturing Method of Absorptive Sodium-Oligopeptide Non-Electrolysis in Human Fluid | |
US7175867B2 (en) | Metastable mineral-amino acid preparations for food and beverage fortification | |
Hajós | Enzymatic modification as a tool for alteration of safety and quality of food proteins | |
JPH0595A (en) | Method for production of peptide or protein product reinforced by covalently bonding amino acid | |
JPH0515389A (en) | Production of protein-like composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |